FDA Begins Hearing on CBD

According to Brightfield Group, a cannabis-focused research firm, the cannabis compound is a booming business with a potential to grow to a $22 billion dollar industry by 2020.

The first of surely more hearing will begin today by the Food and Drug Administration on CBD or Cannabidiol.

CBD or Cannabidiol is derived from hemp and listed as an elixir for a number of ailment from inflammation to epilepsy.

In December of 2018 lawmakers in Congress legalized CBD. Today the nonintoxicating cannabis compound is in everything from makeup, pet treats to soft drinks. This is in direct contradiction of the FDA guidelines which strictly prohibited companies from adding it to food, drinks, and supplements.


According to Brightfield Group, a cannabis-focused research firm, the cannabis compound is a booming business with a potential to grow to a $22 billion dollar industry by 2020. Today’s hearing is to push the FDA to allow them to legally add the compound to food and drinks.

Follow me on Instagram and Twitter @taylorthomas963